D
Psychemedics Corporation
PMDI
$2.30
$0.000.00%
D
Sell
3/6/2025Upgraded
Psychemedics Corporation (PMDI) was upgraded to D- from E+ on 3/6/2025 due to an increase in the total return index, volatility index and growth index.
Psychemedics Corporation (PMDI) was upgraded to D- from E+ on 3/6/2025 due to an increase in the total return index, volatility index and growth index.
E
Sell
1/28/2025Downgrade
Psychemedics Corporation (PMDI) was downgraded to E+ from D- on 1/28/2025 due to a decline in the volatility index and total return index.
Psychemedics Corporation (PMDI) was downgraded to E+ from D- on 1/28/2025 due to a decline in the volatility index and total return index.
D
Sell
1/13/2025Upgraded
Psychemedics Corporation (PMDI) was upgraded to D- from E+ on 1/13/2025 due to a major increase in the growth index, volatility index and solvency index. Operating cash flow increased 119.17% from $120 to $263, earnings per share increased from -$0.1422 to -$0.0908, and EBIT increased 33.82% from -$899 to -$595.
Psychemedics Corporation (PMDI) was upgraded to D- from E+ on 1/13/2025 due to a major increase in the growth index, volatility index and solvency index. Operating cash flow increased 119.17% from $120 to $263, earnings per share increased from -$0.1422 to -$0.0908, and EBIT increased 33.82% from -$899 to -$595.
E
Sell
6/4/2024Downgrade
Psychemedics Corporation (PMD) was downgraded to E+ from D- on 6/4/2024 due to a noticeable decline in the efficiency index, total return index and volatility index. Total capital declined 8.13% from $8.97M to $8.24M.
Psychemedics Corporation (PMD) was downgraded to E+ from D- on 6/4/2024 due to a noticeable decline in the efficiency index, total return index and volatility index. Total capital declined 8.13% from $8.97M to $8.24M.
D
Sell
3/28/2024Upgraded
Psychemedics Corporation (PMD) was upgraded to D- from E+ on 3/28/2024 due to a noticeable increase in the efficiency index, volatility index and total return index. Net income increased 54.98% from -$2.1M to -$945.
Psychemedics Corporation (PMD) was upgraded to D- from E+ on 3/28/2024 due to a noticeable increase in the efficiency index, volatility index and total return index. Net income increased 54.98% from -$2.1M to -$945.
E
Sell
11/17/2023Downgrade
Psychemedics Corporation (PMD) was downgraded to E+ from D- on 11/17/2023 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.17 to 0.19.
Psychemedics Corporation (PMD) was downgraded to E+ from D- on 11/17/2023 due to a large decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.17 to 0.19.
D
Sell
5/23/2023Downgrade
Psychemedics Corporation (PMD) was downgraded to D- from D on 5/23/2023 due to a decline in the total return index and growth index. Operating cash flow declined 111.88% from $1.89M to -$225.
Psychemedics Corporation (PMD) was downgraded to D- from D on 5/23/2023 due to a decline in the total return index and growth index. Operating cash flow declined 111.88% from $1.89M to -$225.
D
Sell
8/15/2022Downgrade
Psychemedics Corporation (PMD) was downgraded to D from D+ on 8/15/2022 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 3,320% from -$10 to -$342, earnings per share declined from $0.007 to -$0.0602, and operating cash flow declined 8.12% from $345 to $317.
Psychemedics Corporation (PMD) was downgraded to D from D+ on 8/15/2022 due to a significant decline in the growth index, solvency index and volatility index. EBIT declined 3,320% from -$10 to -$342, earnings per share declined from $0.007 to -$0.0602, and operating cash flow declined 8.12% from $345 to $317.
D
Sell
5/16/2022Upgraded
Psychemedics Corporation (PMD) was upgraded to D+ from D- on 5/16/2022 due to an increase in the total return index.
Psychemedics Corporation (PMD) was upgraded to D+ from D- on 5/16/2022 due to an increase in the total return index.
D
Sell
5/13/2022Downgrade
Psychemedics Corporation (PMD) was downgraded to D- from D on 5/13/2022 due to a decline in the volatility index.
Psychemedics Corporation (PMD) was downgraded to D- from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/5/2022Upgraded
Psychemedics Corporation (PMD) was upgraded to D from D- on 5/5/2022 due to an increase in the dividend index.
Psychemedics Corporation (PMD) was upgraded to D from D- on 5/5/2022 due to an increase in the dividend index.
D
Sell
4/20/2022Downgrade
Psychemedics Corporation (PMD) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
Psychemedics Corporation (PMD) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
D
Sell
4/18/2022Downgrade
Psychemedics Corporation (PMD) was downgraded to D from C- on 4/18/2022 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from $0.13 to -$0.291, net income declined 319.35% from $739 to -$1.62M, and EBIT declined 213.53% from $850 to -$965.
Psychemedics Corporation (PMD) was downgraded to D from C- on 4/18/2022 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from $0.13 to -$0.291, net income declined 319.35% from $739 to -$1.62M, and EBIT declined 213.53% from $850 to -$965.
C
Hold
3/15/2022Downgrade
Psychemedics Corporation (PMD) was downgraded to C- from C on 3/15/2022 due to a decline in the total return index and volatility index.
Psychemedics Corporation (PMD) was downgraded to C- from C on 3/15/2022 due to a decline in the total return index and volatility index.
C
Hold
2/9/2022Upgraded
Psychemedics Corporation (PMD) was upgraded to C from C- on 2/9/2022 due to an increase in the volatility index and efficiency index.
Psychemedics Corporation (PMD) was upgraded to C from C- on 2/9/2022 due to an increase in the volatility index and efficiency index.
C
Hold
1/25/2022Downgrade
Psychemedics Corporation (PMD) was downgraded to C- from C on 1/25/2022 due to a decline in the volatility index and total return index.
Psychemedics Corporation (PMD) was downgraded to C- from C on 1/25/2022 due to a decline in the volatility index and total return index.
C
Hold
1/10/2022Upgraded
Psychemedics Corporation (PMD) was upgraded to C from C- on 1/10/2022 due to an increase in the volatility index and valuation index.
Psychemedics Corporation (PMD) was upgraded to C from C- on 1/10/2022 due to an increase in the volatility index and valuation index.
C
Hold
12/3/2021Downgrade
Psychemedics Corporation (PMD) was downgraded to C- from C on 12/3/2021 due to a decline in the volatility index.
Psychemedics Corporation (PMD) was downgraded to C- from C on 12/3/2021 due to a decline in the volatility index.
C
Hold
11/18/2021Upgraded
Psychemedics Corporation (PMD) was upgraded to C from C- on 11/18/2021 due to a noticeable increase in the solvency index, total return index and efficiency index. Net income increased 451.49% from $134 to $739, and debt to equity declined from 0.36 to 0.17.
Psychemedics Corporation (PMD) was upgraded to C from C- on 11/18/2021 due to a noticeable increase in the solvency index, total return index and efficiency index. Net income increased 451.49% from $134 to $739, and debt to equity declined from 0.36 to 0.17.
C
Hold
9/28/2021Upgraded
Psychemedics Corporation (PMD) was upgraded to C- from D+ on 9/28/2021 due to an increase in the total return index.
Psychemedics Corporation (PMD) was upgraded to C- from D+ on 9/28/2021 due to an increase in the total return index.
D
Sell
9/13/2021Downgrade
Psychemedics Corporation (PMD) was downgraded to D+ from C- on 9/13/2021 due to a decline in the volatility index and valuation index.
Psychemedics Corporation (PMD) was downgraded to D+ from C- on 9/13/2021 due to a decline in the volatility index and valuation index.
C
Hold
8/25/2021Upgraded
Psychemedics Corporation (PMD) was upgraded to C- from D+ on 8/25/2021 due to an increase in the total return index and volatility index.
Psychemedics Corporation (PMD) was upgraded to C- from D+ on 8/25/2021 due to an increase in the total return index and volatility index.
D
Sell
8/20/2021Upgraded
Psychemedics Corporation (PMD) was upgraded to D+ from D on 8/20/2021 due to a significant increase in the growth index, total return index and solvency index. Operating cash flow increased 257.38% from -$413 to $650, earnings per share increased from $0.01 to $0.02, and EBIT increased 76.92% from $117 to $207.
Psychemedics Corporation (PMD) was upgraded to D+ from D on 8/20/2021 due to a significant increase in the growth index, total return index and solvency index. Operating cash flow increased 257.38% from -$413 to $650, earnings per share increased from $0.01 to $0.02, and EBIT increased 76.92% from $117 to $207.
D
Sell
5/24/2021Downgrade
Psychemedics Corporation (PMD) was downgraded to D from D+ on 5/24/2021 due to a decline in the volatility index.
Psychemedics Corporation (PMD) was downgraded to D from D+ on 5/24/2021 due to a decline in the volatility index.
D
Sell
5/7/2021Upgraded
Psychemedics Corporation (PMD) was upgraded to D+ from D on 5/7/2021 due to an increase in the total return index, volatility index and solvency index.
Psychemedics Corporation (PMD) was upgraded to D+ from D on 5/7/2021 due to an increase in the total return index, volatility index and solvency index.
D
Sell
3/23/2021Downgrade
Psychemedics Corporation (PMD) was downgraded to D from D+ on 3/23/2021 due to a decline in the volatility index.
Psychemedics Corporation (PMD) was downgraded to D from D+ on 3/23/2021 due to a decline in the volatility index.
D
Sell
2/26/2021Upgraded
Psychemedics Corporation (PMD) was upgraded to D+ from D on 2/26/2021 due to a noticeable increase in the volatility index and total return index.
Psychemedics Corporation (PMD) was upgraded to D+ from D on 2/26/2021 due to a noticeable increase in the volatility index and total return index.
D
Sell
3/4/2020Downgrade
Psychemedics Corporation (PMD) was downgraded to D from D+ on 3/4/2020 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.12 to -$0.0961, EBIT declined 85.46% from $1.33M to $194, and debt to equity increased from 0.14 to 0.21.
Psychemedics Corporation (PMD) was downgraded to D from D+ on 3/4/2020 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.12 to -$0.0961, EBIT declined 85.46% from $1.33M to $194, and debt to equity increased from 0.14 to 0.21.
D
Sell
7/23/2019Downgrade
Psychemedics Corporation (PMD) was downgraded to D+ from C- on 7/23/2019 due to a decline in the total return index and volatility index.
Psychemedics Corporation (PMD) was downgraded to D+ from C- on 7/23/2019 due to a decline in the total return index and volatility index.
C
Hold
5/21/2019Downgrade
Psychemedics Corporation (PMD) was downgraded to C- from C on 5/21/2019 due to a noticeable decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.09 to 0.17, and the quick ratio declined from 3.15 to 2.81.
Psychemedics Corporation (PMD) was downgraded to C- from C on 5/21/2019 due to a noticeable decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.09 to 0.17, and the quick ratio declined from 3.15 to 2.81.
C
Hold
2/15/2019Downgrade
Psychemedics Corporation (PMD) was downgraded to C from C+ on 2/15/2019 due to a decline in the valuation index, volatility index and total return index.
Psychemedics Corporation (PMD) was downgraded to C from C+ on 2/15/2019 due to a decline in the valuation index, volatility index and total return index.
C
Hold
1/30/2019Upgraded
Psychemedics Corporation (PMD) was upgraded to C+ from C on 1/30/2019 due to an increase in the total return index.
Psychemedics Corporation (PMD) was upgraded to C+ from C on 1/30/2019 due to an increase in the total return index.
C
Hold
12/19/2018Downgrade
Psychemedics Corporation (PMD) was downgraded to C from C+ on 12/19/2018 due to a decline in the total return index and volatility index.
Psychemedics Corporation (PMD) was downgraded to C from C+ on 12/19/2018 due to a decline in the total return index and volatility index.
C
Hold
11/14/2018Downgrade
Psychemedics Corporation (PMD) was downgraded to C+ from B- on 11/14/2018 due to a noticeable decline in the growth index and total return index. Operating cash flow declined 81.45% from $2.19M to $407.
Psychemedics Corporation (PMD) was downgraded to C+ from B- on 11/14/2018 due to a noticeable decline in the growth index and total return index. Operating cash flow declined 81.45% from $2.19M to $407.
B
Buy
9/24/2018Upgraded
Psychemedics Corporation (PMD) was upgraded to B- from C+ on 9/24/2018 due to an increase in the volatility index, valuation index and dividend index.
Psychemedics Corporation (PMD) was upgraded to B- from C+ on 9/24/2018 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
8/21/2018Upgraded
Psychemedics Corporation (PMD) was upgraded to C+ from C on 8/21/2018 due to an increase in the volatility index.
Psychemedics Corporation (PMD) was upgraded to C+ from C on 8/21/2018 due to an increase in the volatility index.
C
Hold
7/27/2018Downgrade
Psychemedics Corporation (PMD) was downgraded to C from C+ on 7/27/2018 due to a decline in the dividend index.
Psychemedics Corporation (PMD) was downgraded to C from C+ on 7/27/2018 due to a decline in the dividend index.
C
Hold
7/12/2018Upgraded
Psychemedics Corporation (PMD) was upgraded to C+ from C on 7/12/2018 due to an increase in the total return index, valuation index and volatility index.
Psychemedics Corporation (PMD) was upgraded to C+ from C on 7/12/2018 due to an increase in the total return index, valuation index and volatility index.
C
Hold
6/22/2018Downgrade
Psychemedics Corporation (PMD) was downgraded to C from C+ on 6/22/2018 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.42 to $0.2278, operating cash flow declined 30.7% from $2.03M to $1.41M, and EBIT declined 2.06% from $1.95M to $1.91M.
Psychemedics Corporation (PMD) was downgraded to C from C+ on 6/22/2018 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.42 to $0.2278, operating cash flow declined 30.7% from $2.03M to $1.41M, and EBIT declined 2.06% from $1.95M to $1.91M.
C
Hold
3/23/2018Downgrade
Psychemedics Corporation (PMD) was downgraded to C+ from B- on 3/23/2018 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 44.97% from $3.69M to $2.03M, EBIT declined 12.81% from $2.23M to $1.95M, and total revenue declined 2.89% from $10.05M to $9.76M.
Psychemedics Corporation (PMD) was downgraded to C+ from B- on 3/23/2018 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 44.97% from $3.69M to $2.03M, EBIT declined 12.81% from $2.23M to $1.95M, and total revenue declined 2.89% from $10.05M to $9.76M.
B
Buy
1/2/2018Upgraded
Psychemedics Corporation (PMD) was upgraded to B- from C+ on 1/2/2018 due to an increase in the total return index.
Psychemedics Corporation (PMD) was upgraded to B- from C+ on 1/2/2018 due to an increase in the total return index.
C
Hold
11/1/2017Downgrade
Psychemedics Corporation (PMD) was downgraded to C+ from B- on 11/1/2017 due to a significant decline in the total return index and volatility index.
Psychemedics Corporation (PMD) was downgraded to C+ from B- on 11/1/2017 due to a significant decline in the total return index and volatility index.
B
Buy
8/7/2017Downgrade
Psychemedics Corporation (PMD) was downgraded to B- from B on 8/7/2017 due to a decline in the growth index and valuation index. Operating cash flow declined 122.08% from $4.4M to -$972, earnings per share declined from $0.27 to $0.16, and EBIT declined 24.6% from $2.27M to $1.71M.
Psychemedics Corporation (PMD) was downgraded to B- from B on 8/7/2017 due to a decline in the growth index and valuation index. Operating cash flow declined 122.08% from $4.4M to -$972, earnings per share declined from $0.27 to $0.16, and EBIT declined 24.6% from $2.27M to $1.71M.
B
Buy
7/20/2017Upgraded
Psychemedics Corporation (PMD) was upgraded to B from B- on 7/20/2017 due to a large increase in the total return index, valuation index and solvency index. Debt to equity declined from 0.22 to 0.19, and the quick ratio increased from 2.17 to 2.29.
Psychemedics Corporation (PMD) was upgraded to B from B- on 7/20/2017 due to a large increase in the total return index, valuation index and solvency index. Debt to equity declined from 0.22 to 0.19, and the quick ratio increased from 2.17 to 2.29.
B
Buy
3/1/2017Downgrade
Psychemedics Corporation (PMD) was downgraded to B- from B on 3/1/2017 due to a large decline in the total return index and volatility index.
Psychemedics Corporation (PMD) was downgraded to B- from B on 3/1/2017 due to a large decline in the total return index and volatility index.
B
Buy
11/4/2016Upgraded
Psychemedics Corp. (PMD) was upgraded to B from B- on 11/4/2016 due to a significant increase in the growth index, valuation index and solvency index. EBIT increased 73.08% from $2.37M to $4.1M, earnings per share increased from $0.3 to $0.49, and operating cash flow increased 60.18% from $2.26M to $3.63M.
Psychemedics Corp. (PMD) was upgraded to B from B- on 11/4/2016 due to a significant increase in the growth index, valuation index and solvency index. EBIT increased 73.08% from $2.37M to $4.1M, earnings per share increased from $0.3 to $0.49, and operating cash flow increased 60.18% from $2.26M to $3.63M.
B
Buy
9/23/2016Downgrade
Psychemedics Corp. (PMD) was downgraded to B- from B on 9/23/2016 due to a decline in the total return index and volatility index.
Psychemedics Corp. (PMD) was downgraded to B- from B on 9/23/2016 due to a decline in the total return index and volatility index.
B
Buy
9/8/2016Upgraded
Psychemedics Corp. (PMD) was upgraded to B from B- on 9/8/2016 due to a significant increase in the total return index, solvency index and volatility index.
Psychemedics Corp. (PMD) was upgraded to B from B- on 9/8/2016 due to a significant increase in the total return index, solvency index and volatility index.
B
Buy
8/8/2016Upgraded
Psychemedics Corp. (PMD) was upgraded to B- from C+ on 8/8/2016 due to a large increase in the total return index.
Psychemedics Corp. (PMD) was upgraded to B- from C+ on 8/8/2016 due to a large increase in the total return index.
C
Hold
8/1/2016Upgraded
Psychemedics Corp. (PMD) was upgraded to C+ from C on 8/1/2016 due to a significant increase in the growth index, valuation index and total return index. EBIT increased 139,576.47% from -$1.7 to $2.37M, earnings per share increased from -$0.0043 to $0.3, and operating cash flow increased 1,165.9% from $178.9 to $2.26M.
Psychemedics Corp. (PMD) was upgraded to C+ from C on 8/1/2016 due to a significant increase in the growth index, valuation index and total return index. EBIT increased 139,576.47% from -$1.7 to $2.37M, earnings per share increased from -$0.0043 to $0.3, and operating cash flow increased 1,165.9% from $178.9 to $2.26M.
C
Hold
5/18/2016Upgraded
Psychemedics Corp. (PMD) was upgraded to C from C- on 5/18/2016 due to an increase in the total return index, valuation index and dividend index.
Psychemedics Corp. (PMD) was upgraded to C from C- on 5/18/2016 due to an increase in the total return index, valuation index and dividend index.
C
Hold
5/3/2016Downgrade
Psychemedics Corp. (PMD) was downgraded to C- from C on 5/3/2016 due to a decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.0302 to -$0.0043, EBIT declined 101.5% from $113.6 to -$1.7, and operating cash flow declined 93.16% from $2.62M to $178.9.
Psychemedics Corp. (PMD) was downgraded to C- from C on 5/3/2016 due to a decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.0302 to -$0.0043, EBIT declined 101.5% from $113.6 to -$1.7, and operating cash flow declined 93.16% from $2.62M to $178.9.
C
Hold
4/6/2016Upgraded
Psychemedics Corp. (PMD) was upgraded to C from C- on 4/6/2016 due to an increase in the total return index and volatility index.
Psychemedics Corp. (PMD) was upgraded to C from C- on 4/6/2016 due to an increase in the total return index and volatility index.
C
Hold
3/11/2016Downgrade
Psychemedics Corp. (PMD) was downgraded to C- from C on 3/11/2016 due to a large decline in the valuation index, volatility index and total return index.
Psychemedics Corp. (PMD) was downgraded to C- from C on 3/11/2016 due to a large decline in the valuation index, volatility index and total return index.
C
Hold
2/22/2016Downgrade
Psychemedics Corp. (PMD) was downgraded to C from C+ on 2/22/2016 due to a decline in the valuation index and dividend index.
Psychemedics Corp. (PMD) was downgraded to C from C+ on 2/22/2016 due to a decline in the valuation index and dividend index.
C
Hold
12/14/2015Upgraded
Psychemedics Corp. (PMD) was upgraded to C+ from C on 12/14/2015 due to an increase in the valuation index and dividend index.
Psychemedics Corp. (PMD) was upgraded to C+ from C on 12/14/2015 due to an increase in the valuation index and dividend index.
C
Hold
11/27/2015Downgrade
Psychemedics Corp. (PMD) was downgraded to C from C+ on 11/27/2015 due to a decline in the valuation index, solvency index and dividend index. Debt to equity increased from 0.46 to 0.52.
Psychemedics Corp. (PMD) was downgraded to C from C+ on 11/27/2015 due to a decline in the valuation index, solvency index and dividend index. Debt to equity increased from 0.46 to 0.52.
C
Hold
11/2/2015Upgraded
Psychemedics Corp. (PMD) was upgraded to C+ from C on 11/2/2015 due to an increase in the valuation index and dividend index.
Psychemedics Corp. (PMD) was upgraded to C+ from C on 11/2/2015 due to an increase in the valuation index and dividend index.
C
Hold
10/16/2015Downgrade
Psychemedics Corp. (PMD) was downgraded to C from C+ on 10/16/2015 due to a major decline in the total return index, volatility index and growth index. EBIT declined 20.98% from $450.5 to $356, and earnings per share declined from $0.05 to $0.0467.
Psychemedics Corp. (PMD) was downgraded to C from C+ on 10/16/2015 due to a major decline in the total return index, volatility index and growth index. EBIT declined 20.98% from $450.5 to $356, and earnings per share declined from $0.05 to $0.0467.
C
Hold
7/13/2015Downgrade
Psychemedics Corp. (PMD) was downgraded to C+ from B- on 7/13/2015 due to a major decline in the volatility index.
Psychemedics Corp. (PMD) was downgraded to C+ from B- on 7/13/2015 due to a major decline in the volatility index.
B
Buy
6/15/2015Downgrade
Psychemedics Corp. (PMD) was downgraded to B- from B on 6/15/2015 due to a large decline in the volatility index.
Psychemedics Corp. (PMD) was downgraded to B- from B on 6/15/2015 due to a large decline in the volatility index.
B
Buy
5/21/2015Upgraded
Psychemedics Corp. (PMD) was upgraded to B from B- on 5/21/2015 due to an increase in the valuation index and dividend index.
Psychemedics Corp. (PMD) was upgraded to B from B- on 5/21/2015 due to an increase in the valuation index and dividend index.
B
Buy
5/6/2015Downgrade
Psychemedics Corp. (PMD) was downgraded to B- from B on 5/6/2015 due to a noticeable decline in the growth index, valuation index and solvency index. Operating cash flow declined 81.08% from $2.5M to $473.3, earnings per share declined from $0.1258 to $0.05, and EBIT declined 52.96% from $957.7 to $450.5.
Psychemedics Corp. (PMD) was downgraded to B- from B on 5/6/2015 due to a noticeable decline in the growth index, valuation index and solvency index. Operating cash flow declined 81.08% from $2.5M to $473.3, earnings per share declined from $0.1258 to $0.05, and EBIT declined 52.96% from $957.7 to $450.5.
B
Buy
3/2/2015Downgrade
Psychemedics Corp. (PMD) was downgraded to B from B+ on 3/2/2015 due to a noticeable decline in the growth index, valuation index and total return index. Earnings per share declined from $0.17 to $0.1258, EBIT declined 23.03% from $1.24M to $957.7, and total revenue declined 12.23% from $7.7M to $6.76M.
Psychemedics Corp. (PMD) was downgraded to B from B+ on 3/2/2015 due to a noticeable decline in the growth index, valuation index and total return index. Earnings per share declined from $0.17 to $0.1258, EBIT declined 23.03% from $1.24M to $957.7, and total revenue declined 12.23% from $7.7M to $6.76M.
B
Buy
1/22/2015Upgraded
Psychemedics Corp. (PMD) was upgraded to B+ from B on 1/22/2015 due to an increase in the volatility index and total return index.
Psychemedics Corp. (PMD) was upgraded to B+ from B on 1/22/2015 due to an increase in the volatility index and total return index.
B
Buy
11/6/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to B from A- on 11/6/2014 due to a substantial decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.47 to 0.51, and EBIT declined 5.72% from $1.32M to $1.24M.
Psychemedics Corp. (PMD) was downgraded to B from A- on 11/6/2014 due to a substantial decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.47 to 0.51, and EBIT declined 5.72% from $1.32M to $1.24M.
A
Buy
10/31/2014Upgraded
Psychemedics Corp. (PMD) was upgraded to A- from B on 10/31/2014 due to an increase in the volatility index and valuation index.
Psychemedics Corp. (PMD) was upgraded to A- from B on 10/31/2014 due to an increase in the volatility index and valuation index.
B
Buy
10/24/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to B from A- on 10/24/2014 due to a decline in the volatility index.
Psychemedics Corp. (PMD) was downgraded to B from A- on 10/24/2014 due to a decline in the volatility index.
A
Buy
10/21/2014Upgraded
Psychemedics Corp. (PMD) was upgraded to A- from B on 10/21/2014 due to an increase in the volatility index and valuation index.
Psychemedics Corp. (PMD) was upgraded to A- from B on 10/21/2014 due to an increase in the volatility index and valuation index.
B
Buy
10/20/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to B from B+ on 10/20/2014 due to a decline in the volatility index.
Psychemedics Corp. (PMD) was downgraded to B from B+ on 10/20/2014 due to a decline in the volatility index.
B
Buy
10/15/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to B+ from A- on 10/15/2014 due to a decline in the valuation index, volatility index and dividend index.
Psychemedics Corp. (PMD) was downgraded to B+ from A- on 10/15/2014 due to a decline in the valuation index, volatility index and dividend index.
A
Buy
9/29/2014Upgraded
Psychemedics Corp. (PMD) was upgraded to A- from B on 9/29/2014 due to an increase in the valuation index, volatility index and total return index.
Psychemedics Corp. (PMD) was upgraded to A- from B on 9/29/2014 due to an increase in the valuation index, volatility index and total return index.
B
Buy
9/10/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to B from B+ on 9/10/2014 due to a decline in the volatility index.
Psychemedics Corp. (PMD) was downgraded to B from B+ on 9/10/2014 due to a decline in the volatility index.
B
Buy
8/29/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to B+ from A- on 8/29/2014 due to a decline in the valuation index, volatility index and dividend index.
Psychemedics Corp. (PMD) was downgraded to B+ from A- on 8/29/2014 due to a decline in the valuation index, volatility index and dividend index.
A
Buy
8/14/2014Upgraded
Psychemedics Corp. (PMD) was upgraded to A- from B+ on 8/14/2014 due to an increase in the volatility index.
Psychemedics Corp. (PMD) was upgraded to A- from B+ on 8/14/2014 due to an increase in the volatility index.
B
Buy
8/13/2014Upgraded
Psychemedics Corp. (PMD) was upgraded to B+ from B on 8/13/2014 due to an increase in the growth index and volatility index. Earnings per share increased from $0.14 to $0.16, EBIT increased 12.98% from $1.17M to $1.32M, and total revenue increased 9.22% from $7.04M to $7.69M.
Psychemedics Corp. (PMD) was upgraded to B+ from B on 8/13/2014 due to an increase in the growth index and volatility index. Earnings per share increased from $0.14 to $0.16, EBIT increased 12.98% from $1.17M to $1.32M, and total revenue increased 9.22% from $7.04M to $7.69M.
B
Buy
7/21/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to B from B+ on 7/21/2014 due to a decline in the volatility index.
Psychemedics Corp. (PMD) was downgraded to B from B+ on 7/21/2014 due to a decline in the volatility index.
B
Buy
7/18/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to B+ from A- on 7/18/2014 due to a substantial decline in the volatility index and total return index.
Psychemedics Corp. (PMD) was downgraded to B+ from A- on 7/18/2014 due to a substantial decline in the volatility index and total return index.
A
Buy
6/13/2014Downgrade
Psychemedics Corp. (PMD) was downgraded to A- from A on 6/13/2014 due to a decline in the volatility index, valuation index and dividend index.
Psychemedics Corp. (PMD) was downgraded to A- from A on 6/13/2014 due to a decline in the volatility index, valuation index and dividend index.
A
Buy
5/29/2014Upgraded
Psychemedics Corp. (PMD) was upgraded to A from A- on 5/29/2014 due to a major increase in the volatility index, growth index and valuation index. EBIT increased 13.06% from $1.03M to $1.17M, and total revenue increased 8.65% from $6.48M to $7.04M.
Psychemedics Corp. (PMD) was upgraded to A from A- on 5/29/2014 due to a major increase in the volatility index, growth index and valuation index. EBIT increased 13.06% from $1.03M to $1.17M, and total revenue increased 8.65% from $6.48M to $7.04M.
OTC PK
03/07/2025 11:37AM Eastern
Quotes delayed
